Published: 2017-01-04

Expression and modulation of complement receptor 2 (CR2/CD21) in the pathophysiology of rheumatoid arthritis

Rozaleen Dash, Uma Kumar, Maumita Kanjilal, Nibhriti Das


Background: The involvement of B cells, complement activation and subsequent immune complex deposition has been implicated in the pathogenesis of rheumatoid arthritis (RA). Although the reduced expression of complement receptor 2 (CR2, CD21) on the B cells of RA patients is known for long, we aimed at determining the modulation and expression of CR2 on PBMC of healthy individuals and RA patients.

Methods: Sixty controls and 57 RA patients were enrolled. PBMC-CR2 transcript levels were correlated with the levels of C3, C3d and circulating immune complexes (CIC) in controls and patients and with DAS28 in patients only. CIC levels were determined by PEG precipitation, C3 levels by nephlometry and C3d levels were determined by enzyme linked immunosorbent assay (ELISA). Sixteen patients were recruited for 6 months follow up studies of transcript levels of PBMC correlated with DAS28 score. Appropriate statistical methods were used for the analyses of data.

Results: PBMC- CR2 transcript levels were declined in patients as compared to controls. PBMC-CR2 levels correlated negatively with DAS28 score. DAS28 correlated positively with levels of CIC, C3 and C3d. Levels of PBMC -CR2 increased in patients with decline in DAS28 scores in 6 months follow-up patients.

Conclusions: Low level of CR2 expression in patients may, thus, contribute significantly to the pathological manifestation of RA. Cause-effect relationships of the up regulation of CR2 on improvement of health condition with the pathophysiology of RA and their importance as putative disease markers is being confirmed.



Rheumatoid arthritis, Complement receptor, Transcript, DAS-28, Disease marker

Full Text:



Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85:307-310.

Coico R, Sunshine G. Immunology: A Short Course. 6th ed. Hoboken, NJ: John Wiley and Sons; 2009.

Imboden JB, Stone JH, Hellmann DB. Current Rheumatology, Diagnosis and Treatment. 2nd ed. New York, NY: Lange Medical Books, McGraw- hill; 2007.

Shibuya T, Izuchi K, Kuroiwa A, Harada H, Kumamoto A, Shirakawa K. Study on nonspecific immunity in pregnant women: II. Effect of hormones on chemiluminescence response of peripheral blood phagocytes. Am J Reprod Immunol. 1991;26(2):76-81.

O'Neill SK, Shlomchik MJ, Glant TT, Cao Y, Doodes PD, Finnegan A. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J. Immunol. 2005;174:3781-88.

Larsen CP, Knechtle SJ, Adams A. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immuno-suppression. Am J Transplant. 2006;6:876-83.

Hikada M, Zouali M. Multistoried roles for B lymphocytes in autoimmunity. Nat. Immunol. 2010;11:1065-8.

Liu D, Zhu JY, Niu ZX. Molecular structure and expression of anthropic, ovine and murine forms of Complement receptor type 2. Clin and vac Immunl. 2008;15:901-10.

Ahearn JM, Fearon DT. Structure and function of the C receptors, CR1 (CD35) and CR2 (CD21). Adv. Immunol. 1989;46:183-219.

Delibrias CC, Fischer E, Bismuth G and Kazatchkine MD. Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL. J Immunol. 1992;149:768-74.

Fischer E, Delibrias C, Kazatchkine MD. Expression of CR2 (the C dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J.Immunol. 1991;141(6):865-9.

Kremlitzka M, Polgár A, Fülöp L, Kiss E, Poór G, Erdei A. Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patients. Int. Immunol. 2012. doi: 10.1093/intimm/dxs090.

Arnett FC, Edworthy SM, Bloch D. The American Rheumatism Association 1987 revised criteria for the classification of Rheumatoid Arthritis. Arthritis Rheum. 1988;31:315-24.

Chang H, Gwack Y, Kingston D, Souvlis J, Liang X, Means RE, et al. Activation of CD21 and CD23 gene expression by Kapsi’s sarcoma- associated herpes virus. J of Virol. 2005;79(8):4651-63.

Sai Baba KSS, Moudgil KD, Jain RC, Srivastava LM. Complement activation in pulmonary tuberculosis. Tubercle. 1990;71:103-7.

Roome AJ, Reading CL. Frequency of B- lymphocyte transformation by Epstein - Barr virus decreases with entry into the cell cycle. Immunol. 1987;60:195-201.

Illges H, Braun M, Peter HH, Melchers I. Reduced expression of the complement receptor type 2 (CR2, CD21) by synovial fluid B and T lymphocytes. Clin. Exp. Immunol. 2000;122:270-6.

Prokopec KE, Rhodiner M, Vrohlings M, Matt P, Lindqvist U, Kleinau S. Down-regulation of Fc and complement receptors on B cells in rheumatoid arthritis. Clin Immunol. 2010;137(3):322-9.

Alper CA, Rosen FS. Studies of the in vivo behavior of human C3 in normal subjects and patients. J Clin Invest. 1967;46:2021-34.

Hunsicker LG, Ruddy S, Carpenter CB, Schur PH, Merrill JP, Muller-Eberhard HJ et al. Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med. 1972;287:835-40.

Ashizawa T, Appel SH: Immunopathologic events at the endplate in myasthenia gravis. Springer Semin Immunopathol. 1985;8:177-96.

Cavallo T. Membranous nephropathy. Insights from Heymann nephritis. Am J Pathol. 1994;144:651-8.

Couser WG. Glomerulonephritis. Lancet. 1999;353:1509-15.

Morrow WJW, Williams DJP, Ferec C, Casburn – budd R, Isenberg DA, Paice E, et al. The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis. Annals of Rheu. Diseases. 1983;42:668-71.

Mallya RK, Vergani D, Tee DE , Bevis L, de Beer FC, Berry H, et al. Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity. Clin Exp Immunol. 1982;48:747-53.

Perrin LH, Lambert PH, Miescher PA. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membrano-proliferative or other glomerulonephritis. J Clin Invest. 1975;56:165-76.

Schifferli JA, Taylor RP. Physiological and Pathological aspects of circulating immune complexes. Kidney Int. 1989;35:993-1003.